Randomized phase III trial of weekly compared with every-3-weeks paclitaxel for metastatic breast cancer, with trastuzumab for all HER-2 overexpressors and random assignment to trastuzumab or not in HER-2 nonoverexpressors: final results of Cancer and...
| Autor: | Seidman AD, Berry D, Cirrincione C, Harris L, Muss H, Marcom PK, Gipson G, Burstein H, Lake D, Shapiro CL, Ungaro P, Norton L, Winer E, Hudis C |
|---|---|
| Zdroj: | Journal of Clinical Oncology; 4/1/2008, Vol. 26 Issue 10, p1642-1649, 8p |
| Databáze: | Supplemental Index |
| Externí odkaz: |
|